PARIS, France, July 9, 2026
Ipsen has announced positive topline Phase III results from its BEOND clinical development program, demonstrating that Dysport® (abobotulinumtoxinA) successfully met the primary endpoints in both episodic migraine (E-BEOND) and chronic migraine (C-BEOND) clinical trials. The results establish Dysport as the first botulinum toxin to demonstrate statistically significant Phase III efficacy in both episodic and chronic migraine prevention, representing a major milestone in the development of preventive therapies for one of the world’s most disabling neurological disorders. Across both studies, Dysport significantly reduced monthly migraine days compared with placebo while maintaining a well-established safety profile consistent with its approved therapeutic indications. The findings position Dysport as a potential first-in-class preventive treatment capable of addressing a broad migraine population and support Ipsen’s expanding neuroscience portfolio focused on innovative therapies for patients with high unmet medical needs.
BEOND Program Achieves Landmark Phase III Success
The BEOND Phase III clinical program consisted of two randomized, multicenter, placebo-controlled studies—E-BEOND evaluating episodic migraine and C-BEOND evaluating chronic migraine—enrolling a total of 1,510 patients across 120 clinical centers worldwide. Both studies achieved their primary endpoint by demonstrating a statistically significant reduction in monthly migraine days at Week 24 compared with placebo. Notably, the E-BEOND trial marks the first Phase III study in which a botulinum toxin has demonstrated statistically significant efficacy in preventing episodic migraine, while the combined success of both studies makes BEOND the first Phase III clinical program to establish efficacy of a botulinum toxin across both major migraine populations.
Dysport was also well tolerated, with no unexpected safety findings identified and an overall safety profile consistent with more than 30 years of global clinical experience and over 21 million patient treatment-years across approved indications. The extension phase of both studies will continue through Week 48, providing additional long-term efficacy and safety data.
Potential New Preventive Option for Migraine Patients
Advertisement
Migraine affects approximately 14% of the global population and remains one of the leading causes of neurological disability worldwide, significantly impacting patients’ ability to work, maintain social activities, and preserve quality of life. While individuals with chronic migraine experience at least 15 headache days per month, patients with episodic migraine represent a substantially larger population experiencing up to 14 headache days monthly, creating considerable demand for additional preventive treatment options. Dysport, an injectable botulinum neurotoxin type A, works by inhibiting nerve impulse transmission and reducing muscular activity, and is currently approved in approximately 90 countries for multiple therapeutic indications.
The positive Phase III BEOND results significantly strengthen Ipsen’s neuroscience pipeline and support future regulatory submissions aimed at expanding Dysport’s approved indications to include migraine prevention. If approved, Dysport could provide physicians with an important new preventive treatment option capable of addressing both episodic and chronic migraine through a single, clinically validated therapeutic approach. The successful completion of the BEOND program represents a significant advancement in migraine therapeutics and highlights Ipsen’s continued commitment to developing innovative neuroscience treatments that improve patient outcomes while addressing major unmet needs in neurological disease management.
Source: Ipsen press release
